Ultragenyx Gene Therapy Is First Approved Treatment for Rare Neuro Disease Sanfilippo

Ultragenyx Pharmaceutical’s Fayuvi is now the first FDA-approved therapy for the underlying cause of Sanfilippo syndrome type A, an ultra-rare inherited neurological disorder. It’s the second approved gene therapy for Ultragenyx, which specializes in rare disease medicines. The post Ultragenyx Gene Therapy Is First Approved Treatment for Rare Neuro Disease Sanfilippo appeared first on MedCity…

Read More

Employers Press Congress To Cement Health Price Transparency Before Trump’s Return

It seems simple: Require hospitals and insurers to post their negotiated prices for most health care services and — bingo — competition follows, yielding lower costs for consumers. But nearly four years after the first Trump administration’s regulations forced hospitals to post massive amounts of pricing information online, the effect on patients’ costs is unclear….

Read More

Public Health Departments Face a Post-Covid Funding Crash

During the coronavirus pandemic, states received a rush of funding from the federal government to bolster their fight against the disease. In many cases, that cash flowed into state and local health departments, fueling a staffing surge to handle, among other things, contact tracing and vaccination efforts. But public health leaders quickly identified a familiar…

Read More